Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors.
| Autor: | Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, Hollingsworth S, Baselga J, Umana P, Manenti L, Tabernero J |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 10/1/2011, Vol. 29 Issue 28, p3783-3790, 8p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|